Search
Lanadelumab
go.drugbank.com/drugs/DB14597ApprovedInvestigational[A38676] Lanadelumab was approved for use in patients with hereditary angioedema by the FDA in August 2018,[L4537] followed by Health Canada in October 2018[L49226] and the EMA in November 2018. … [L4538] It is a fully human immunoglobulin, k-light-chain made in recombinant Chinese Hamster Ovary cells.
Categories: Blood and Blood Forming Organs, Amino Acids, Peptides, and ProteinsFlurandrenolide
go.drugbank.com/drugs/DB00846ApprovedIt is usually employed as a cream or an ointment, and is also used as a polyethylene tape with an adhesive. (From Martindale, The Extra Pharmacopoeia, 30th ed, p733)
Categories: fludroxycortide and antibiotics, Hormones, Hormone Substitutes, and Hormone AntagonistsNeoplasms
go.drugbank.com/conditions/DBCOND0027948Synonyms: Neoplasms benign, malignant and unspecified (incl cysts and polyps)Alpha-2-macroglobulin
go.drugbank.com/bio_entities/BE0000910TargetCarrierHumansFollowing cleavage in the bait region, a thioester bond is hydrolyzed and mediates the covalent binding of the protein to the proteinase
Synonyms: C3 and PZP-like alpha-2-macroglobulin domain-containing protein 5GPI-linked NAD(P)(+)--arginine ADP-ribosyltransferase 1
go.drugbank.com/bio_entities/BE0000931TargetHumansHas ADP-ribosyltransferase activity toward GLP1R
Synonyms: ADP-ribosyltransferase C2 and C3 toxin-like 1Respiratory Infection
go.drugbank.com/conditions/DBCOND0034122Synonyms: Recurrent Upper and Lower Respiratory Tract Infections (RTIs)Ecallantide
go.drugbank.com/drugs/DB05311ApprovedApart from its FDA and EMA indication, ecallantide has been used off label in the management of nonhistaminergic angioedema, not due to HAE [A32017]. … Ecallantide is marketed by FDA and EMA under the trade name Kalbitor for subcutaneous injection.
Categories: Blood and Blood Forming Organs, Amino Acids, Peptides, and ProteinsFexinidazole
go.drugbank.com/drugs/DB12265Approved[A237555, A237560] Fexinidazole received a positive opinion from the European Medicines Agency (EMA) in November 2018 and was approved by the FDA on July 16, 2021. … all-oral treatment for first and second stage HAT caused by _T. brucei gambiense_.
Categories: Agents Against Leishmaniasis and Trypanosomiasis, Antiparasitic Products, Insecticides and RepellentsThromboembolism
go.drugbank.com/conditions/DBCOND0022145Synonyms: Embolism and thrombosis of unspecified siteBarbexaclone
go.drugbank.com/drugs/DB09001ExperimentalBarbexaclone exists in 25mg and 100mg tablets. 100mg of barbexaclone is equivalent to 60mg of phenobarbital. … Several reports from Spanish and Italian literature suggest that barbexaclone is at least as effective as phenobarbital in adults and children, while being better tolerated and having less sedative properties
Categories: Barbiturates and Derivatives